Chen, Shuming
Crabill, George A.
Pritchard, Theresa S.
McMiller, Tracee L.
Wei, Ping
Pardoll, Drew M.
Pan, Fan
Topalian, Suzanne L.
Funding for this research was provided by:
National Cancer Institute (R01 CA142779)
National Institutes of Health (R01 AI089830)
Melanoma Research Alliance (N/A)
Article History
Received: 2 July 2019
Accepted: 2 October 2019
First Online: 15 November 2019
Ethics approval and consent to participate
: The use of human tissues in this study was approved by the Johns Hopkins Institutional Review Board.
: Not applicable.
: DMP and SLT report stock and other ownership interests from Aduro Biotech, Compugen, DNAtrix, Dragonfly Therapeutics, ERVAXX, Five Prime Therapeutics, FLX Bio, Jounce Therapeutics, Potenza Therapeutics, Tizona Therapeutics, and WindMIL; consulting or advisory role with AbbVie, Amgen, Bayer, Compugen, DNAtrix, Dragonfly Therapeutics, Dynavax, ERVAXX, Five Prime Therapeutics, FLX Bio, lmmunomic Therapeutics, Janssen Oncology, Medlmmune, Merck, Tizona Therapeutics, and Wind MIL; research funding from Bristol-Myers Squibb, Compugen, and Potenza Therapeutics; patents, royalties, and other intellectual property from Aduro Biotech, Bristol-Myers Squibb, and lmmunonomic Therapeutics; and travel, accommodations, expenses from Bristol-Myers Squibb, and Five Prime Therapeutics. SC, GAC, TSP, PW, TLM and FP have no conflicts of interest to disclose.